ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Paediatrics
Research Topic : skeletal development
Clear All
Filter by Field of Research
Paediatrics (71)
Clinical Social Work Practice (1)
Early childhood education (1)
Infant and child health (1)
Paediatrics and Reproductive Medicine (1)
Public health nutrition (1)
Filter by Socio-Economic Objective
Behaviour and Health (1)
Child health (1)
Neonatal and Child Health (1)
Teacher and Instructor Development (1)
Youth/child development and welfare (1)
Filter by Funding Provider
National Health and Medical Research Council (69)
Australian Research Council (2)
Filter by Status
Closed (70)
Active (1)
Filter by Scheme
NHMRC Project Grants (27)
Project Grants (24)
Early Career Fellowships (4)
Postgraduate Scholarships (4)
Career Development Fellowships (2)
Practitioner Fellowships (2)
Centre for Research Excellence (1)
Centres of Research Excellence (1)
Discovery Early Career Researcher Award (1)
Linkage Projects (1)
NHMRC Research Fellowships (1)
Practitioner Fellowship (1)
Research Fellowships (1)
Targeted Calls (1)
Filter by Country
Australia (9)
Filter by Australian State/Territory
VIC (7)
NSW (2)
QLD (2)
ACT (1)
SA (1)
WA (1)
  • Researchers (3)
  • Funded Activities (71)
  • Organisations (21)
  • Funded Activity

    Towards An Improved Therapy For MPS Disorders

    Funder
    National Health and Medical Research Council
    Funding Amount
    $467,940.00
    Summary
    Mucopolysaccharidoses (MPS) are a related group of 11 debilitating genetic disorders affecting children. They result from a reduction or total deficiency of an enzyme required for the removal of carbohydrate structures called glycosaminoglycans (gags). Gag degradation occurs inside the cell in specific organelles termed lysosomes and in the absence of the appropriate enzyme, undegraded gag accumulates in the cell. This leads to a range of clinical symptoms and multiple tissue failure. Symptoms c .... Mucopolysaccharidoses (MPS) are a related group of 11 debilitating genetic disorders affecting children. They result from a reduction or total deficiency of an enzyme required for the removal of carbohydrate structures called glycosaminoglycans (gags). Gag degradation occurs inside the cell in specific organelles termed lysosomes and in the absence of the appropriate enzyme, undegraded gag accumulates in the cell. This leads to a range of clinical symptoms and multiple tissue failure. Symptoms common to more than one MPS type include mental deterioration, blindness, abdominal organ enlargement and bone growth problems leading to short stature and bone loss. My laboratory has had a long-term interest in developing treatment for MPS and our research led to the clinical implementation of enzyme replacement therapy (ERT) for MPS VI in 2005. While providing the first effective, multi-tissue treatment for MPS, our research showed that several tissues were not responsive to ERT. These are the brain, cartilage and cornea, thus children on ERT regimens will still suffer from mental retardation, arthritis and blindness. With the goal of treating these particular tissues we have developed a new approach to MPS therapy called substrate deprivation therapy (SDT). Instead of adding back the missing enzyme, SDT acts by decreasing gag production which in turn reduces the level of accumulated gag in cells. SDT results in the correction of MPS cells in culture and reduces several key clinical symptoms in the mouse model of MPS IIIA. In this proposal we will extend our research to evaluate the effect of SDT on brain and bone-joint pathology. Evaluation of efficacy will take place in the MPS VII mouse which exhibits both brain and bone disease and in a new model of MPS IVA developed specifically for this study which exhibits a joint pathology unique amongst the MPS disorders.
    Read more Read less
    More information
    Funded Activity

    Gene Therapy For Skeletal Disease In MPS.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $383,783.00
    Summary
    Skeletal disease is a major problem for children with mucopolysaccharidoses (MPS). Patients suffer from early onset osteoporosis and osteoarthritis, severely affecting their quality of life. We will evaluate a lentiviral gene therapy vector developed in-house for its capacity to transduce bone, cartilage, synovial and ligament cells in a mouse model of MPS VI. Our goal is to generate high level, sustained expression of the deficient MPS enzyme and alter the course of skeletal disease in MPS.
    More information
    Funded Activity

    Modern Chemical Exposures In Utero And In Infancy, And Their Impact Upon Early Neurodevelopmental Outcomes In The Barwon Infant Study, An Unselected Birth Cohort Study

    Funder
    National Health and Medical Research Council
    Funding Amount
    $138,353.00
    Summary
    I am a paediatric doctor interested in the effects of modern industrial chemicals on children’s development. Even in the womb babies are exposed to industrial chemicals and we know some, like lead, are harmful to developing brains. I am interested in other chemicals that are now suspected to affect development, including the polybrominated diphenyl esters (PBDEs), and I intend to investigate this as part of the Barwon Infant Study, which follows 1250 children from before birth to 3 years.
    More information
    Funded Activity

    Being Born Small Is Not Good For The Heart:early Detection Of Cardiovascular Risk

    Funder
    National Health and Medical Research Council
    Funding Amount
    $486,757.00
    Summary
    Intra uterine growth restriction(IUGR) is linked to adult onset of cardiovascular disease. However, little is known about the mechanism(s) which underlie this link or which babies are most at risk. This study aims to assess cardiovascular function in infants and children who were growth restricted. Early identification of cardiovascular dysfunction may aid in new opportunities for monitoring and therapeutic targets to ultimately reduce later onset of cardiovascular morbidity in this population.
    More information
    Funded Activity

    DETERMINING THE MECHANISMS LEADING TO LONG-TERM IMPAIRMENT IN VERY PRETERM CHILDREN: THE VIBeS LONGITUDINAL STUDY.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,061,733.00
    Summary
    Approximately 50% of children born very preterm will develop significant problems. The objective of this project is to determine the mechanisms leading to these problems. We will do this by assessing at school-age a unique and valuable cohort of very preterm infants (VIBeS cohort) who had state-of-the-art brain scans shortly after birth and neurobehaviour assessments across early childhood. This school-age follow-up will involve repeat brain scans and detailed neuropsychological assessments.
    More information
    Funded Activity

    Improving Community Approaches For High-prevalence Childhood Conditions

    Funder
    National Health and Medical Research Council
    Funding Amount
    $395,600.00
    More information
    Funded Activity

    Neurodevelopmental Outcomes After Novel Interventions In Newborn Infants

    Funder
    National Health and Medical Research Council
    Funding Amount
    $188,226.00
    Summary
    Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 .... Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 years old.
    Read more Read less
    More information
    Funded Activity

    Immune-regulation By Milk Extracts In Vitro As Well As In Vivo In An Animal Model Of Formula Feeding

    Funder
    National Health and Medical Research Council
    Funding Amount
    $369,500.00
    More information
    Funded Activity

    The Cause Of Undescended Testis And Inguinal Hernia

    Funder
    National Health and Medical Research Council
    Funding Amount
    $743,848.00
    Summary
    This study aims to define in both animal models and children how the testis descends from the abdomen to scrotum, and how undescended testis and inguinal hernia are likely to be caused by defects in the same, very indirect signalling pathway. The results will demonstrate where to look for genetic causes and proof of principle for possible future medical treatments for the 3 commonest major operations in children for congenital and acquired undescended testis and inguinal hernia.
    More information
    Funded Activity

    Contribution To Concensus Conference

    Funder
    National Health and Medical Research Council
    Funding Amount
    $3,500.00
    More information

    Showing 1-10 of 71 Funded Activites

    • 1
    • 2
    • 3
    • 4
    • 5
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback